AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04246385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Group
Description: Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework
Study NCT01856543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eucerin
Study NCT01856543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate 0.1%
Study NCT01180712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mirtoselect
Description: Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.
Study NCT01180712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mirtoselect
Description: Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.
Study NCT02989207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
Study NCT02989207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt tube surgery
Description: All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
Study NCT02989207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitomycin-C
Description: This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
Study NCT03212625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Cream 20%
Description: Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
Study NCT03212625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
Study NCT00075829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Autologous Transplant
Description: Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) > 500/mm3 for two days.
Study NCT00075829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Myeloablative Allogeneic Transplant
Description: Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
Study NCT00075829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second Autologous Transplant
Description: Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
Study NCT00075829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
Study NCT00075829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
Study NCT00075829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: One year of observation post-transplants.
Study NCT03619421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: 25 mg
Study NCT02188485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Up to 10 sessions delivered in the home.
Study NCT04341974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine
Description: Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
Study NCT04043195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
Study NCT04043195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
Study NCT04043195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
Study NCT04521491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
Description: FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
Study NCT03109678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™
Description: After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
Study NCT03109678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover Ambu Aura-i™ / LMA ETT™
Description: After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
Study NCT03109678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover FASTRACH™ / Rüsch Super Safety Silk™
Description: After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
Study NCT03109678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover FASTRACH™ / LMA ETT™
Description: After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.2mg
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.4mg
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1201
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1303 capsule 5/0.2mg placebo
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.2mg placebo
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1303 capsule 5/0.4mg placebo
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.4mg placebo
Study NCT02667938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201 placebo
Study NCT02164552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D3 pills
Description: Dietary supplement
Study NCT02164552 — intervention group
Intervention type: OTHER
Intervention: Placebo pills
Description: Placebo pills similar in appearance and shape but without vitamin D
Study NCT00043693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Intervention for Dual Diagnosis
Description: The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
Study NCT00043693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family psychoeducation program
Description: The family psychoeducation program consists of 6 weekly sessions.
Study NCT03044197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/ultrasound transperineal prostate biopsy
Description: 3-6 targeted biopsy cores from each prostate region of interest
Study NCT03044197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transrectal ultrasound-guided prostate biopsy
Description: 12 systematic biopsy cores
Study NCT03657472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30061
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
Study NCT03657472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® 5/160mg & Lipitor® 20mg
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
Study NCT01971346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: 100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
Study NCT01971658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide®
Study NCT01971658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT01971658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade®
Study NCT01971658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexaméthasone
Study NCT02320890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YBand (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02320890 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-YBand (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT05738200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
Study NCT01583465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys
Description: Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
Study NCT01583465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard electrocautery (Bovie)
Description: Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
Study NCT04130555 — intervention group
Intervention type: DEVICE
Intervention: CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)
Description: Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
Study NCT00758511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25% Sucrose
Description: orally administrated 25%Sucrose before, during and after heel stick
Study NCT00758511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facilitated tucking
Description: facilitated tucking before, during and after heel stick
Study NCT00758511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose and facilitated tucking
Description: orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
Study NCT01639027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine
Description: 40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
Study NCT01639027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
Study NCT01652716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly suspension
Description: Exenatide suspension 2 mg weekly subcutaneous injection
Study NCT01652716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide twice daily
Description: 5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
Study NCT01045304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT02942537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Description: Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
Study NCT02942537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery embolization
Description: Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
Study NCT02585193 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Watchers Intervention
Description: All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
Study NCT00826878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated.
Study NCT04205864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombi-Gel
Description: Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
Study NCT04205864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pelvic lymphadenectomy
Description: Conventional Pelvic lymphadenectomy
Study NCT05259748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors
Description: Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
Study NCT01035229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
Study NCT01035229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
Study NCT01035229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Study NCT01035229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Study NCT03818542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: intravenous infusion
Study NCT01045304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01045304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01725568 — intervention group
Intervention type: DEVICE
Intervention: BioMonitor
Description: Implantable cardiac monitor